K. Usuba, V. E. Price, and V. Blanchette, Impact of prophylaxis on health-related quality of life of boys with hemophilia: an analysis of pooled data from 9 countries, Res Pract Thromb Haemost, vol.3, pp.397-404, 2019.

C. D. Thornburg and N. A. Duncan, Treatment adherence in hemophilia, Patient Prefer Adherence, vol.11, pp.1677-1686, 2017.

L. Graf, Extended half-life factor VIII and factor IX preparations, Transfus Med Hemother, vol.45, pp.86-91, 2018.

T. Rath, K. Baker, and J. A. Dumont, Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics, Crit Rev Biotechnol, vol.35, pp.235-254, 2015.

M. E. Mancuso and P. M. Mannucci, Fc-fusion technology and recombinant FVIII and FIX in the management of the hemophilias, Drug Des Devel Ther, vol.8, pp.365-371, 2014.

J. Mahlangu, J. S. Powell, and M. V. Ragni, Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A, Blood, vol.123, pp.317-325, 2014.

J. S. Powell, N. C. Josephson, and D. Quon, Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients, Blood, vol.119, pp.3031-3037, 2012.

B. Nolan, J. Mahlangu, and D. Perry, Long-term safety and efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with haemophilia A, Haemophilia, vol.22, pp.72-80, 2016.

G. Young, J. Mahlangu, and R. Kulkarni, Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A, J Thromb Haemost, vol.13, pp.967-977, 2015.

B. Nolan, J. Mahlangu, and I. Pabinger, Recombinant factor VIII Fc fusion protein for the treatment of severe haemophilia A: final results from the ASPIRE extension study, Haemophilia, vol.26, pp.494-502, 2020.

F. Peyvandi, I. Garagiola, M. Boscarino, A. Ryan, C. Hermans et al., Real-life experience in switching to new extended half-life products at European haemophilia centres, Haemophilia, vol.25, pp.946-952, 2019.

M. Scott, H. Xiang, P. W. Collins, and C. R. Hay, The effect of switching to rFVIIIFc on treatment patterns and annualised bleed rate before and after: a within-patient comparison from the UK National Haemophilia Database, Haemophilia, vol.24, pp.3-196, 2018.

A. Tagliaferri, A. Matichecchia, and G. F. Rivolta, Optimising prophylaxis outcomes and costs in haemophilia patients switching to recombinant FVIII-Fc: a single-centre real-world experience, Blood Transfus, vol.2019, pp.1-11

C. Wang and G. Young, Clinical use of recombinant factor VIII Fc and recombinant factor IX Fc in patients with haemophilia A and B, Haemophilia, vol.24, pp.414-419, 2018.

R. S. Blumberg and D. Lillicrap, the IgG Fc Immune Tolerance Group. Tolerogenic properties of the Fc portion of IgG and its relevance to the treatment and management of hemophilia, Blood, vol.131, pp.2205-2214, 2018.

Y. Borel, Haptens bound to self IgG induce immunologic tolerance, while when coupled to syngeneic spleen cells they induce immune suppression, Immunol Rev, vol.50, pp.71-104, 1980.

T. J. Waldschmidt, Y. Borel, and E. S. Vitetta, The use of haptenated immunoglobulins to induce B cell tolerance in vitro. The roles of hapten density and the Fc portion of the immunoglobulin carrier, J Immunol, vol.131, pp.2204-2209, 1983.

C. N. Baxevanis, C. D. Ioannides, G. J. Reclos, and M. Papamichail, Evidence for distinct epitopes on human IgG with T cell proliferative and suppressor function, Eur J Immunol, vol.16, pp.1013-1016, 1986.

A. Ephrem, S. Chamat, and C. Miquel, Expansion of CD4 + CD25 + regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis, Blood, vol.111, pp.715-722, 2008.

E. T. Zambidis and D. W. Scott, Epitope-specific tolerance induction with an engineered immunoglobulin, Proc Natl Acad Sci U S A, vol.93, pp.5019-5024, 1996.

A. Kessel, H. Ammuri, and R. Peri, Intravenous immunoglobulin therapy affects T regulatory cells by increasing their suppressive function, J Immunol, vol.179, pp.5571-5575, 2007.

A. S. De-groot, M. L. Mcmurry, and J. A. , Activation of natural regulatory T cells by IgG Fc-derived peptide, Tregitopes". Blood, vol.112, pp.3303-3311, 2008.

J. Mccue, R. Kshirsagar, and K. Selvitelli, Manufacturing process used to produce long-acting recombinant factor VIII Fc fusion protein, Biologicals, vol.43, pp.213-219, 2015.

N. Leksa, B. Pearse, and A. Goodman, Identification of FIXa-and FXspecific antibodies for the generation of bispecific antibodies with FVIIIa-like activity, Res Pract Thromb Haemost, vol.1, pp.1-1451, 2017.

L. A. Valentino, C. L. Kempton, R. Kruse-jarres, P. Mathew, S. L. Meeks et al., US Guidelines for immune tolerance induction in patients with haemophilia A and inhibitors, Haemophilia, vol.21, pp.559-567, 2015.

C. Witmer and G. Young, Factor VIII inhibitors in hemophilia A: rationale and latest evidence, Ther Adv Hematol, vol.4, pp.59-72, 2013.

M. Ing, N. Gupta, and M. Teyssandier, Immunogenicity of long-lasting recombinant factor VIII products, Cell Immunol, vol.301, pp.40-48, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01292437

M. Osooli and E. Berntorp, Inhibitors in haemophilia: what have we learned from registries? A systematic review, J Intern Med, vol.277, pp.1-15, 2015.

T. C. Lei and D. W. Scott, Induction of tolerance to factor VIII inhibitors by gene therapy with immunodominant A2 and C2 domains presented by B cells as Ig fusion proteins, Blood, vol.105, pp.4865-4870, 2005.

S. Culina, N. Gupta, and R. Boisgard, Materno-fetal transfer of preproinsulin through the neonatal Fc receptor prevents autoimmune diabetes, Diabetes, vol.64, pp.3532-3542, 2015.

N. Gupta, S. Culina, and Y. Meslier, Regulation of immune responses to protein therapeutics by transplacental induction of T cell tolerance, Sci Transl Med, vol.7, pp.275-296, 2015.
URL : https://hal.archives-ouvertes.fr/hal-02425481

S. Krishnamoorthy, T. Liu, and D. Drager, Recombinant factor VIII Fc (rFVIIIFc) fusion protein reduces immunogenicity and induces tolerance in hemophilia A mice, Cell Immunol, vol.301, pp.30-39, 2016.

K. Kis-toth, G. M. Rajani, and A. Simpson, Recombinant factor VIII Fc fusion protein drives regulatory macrophage polarization, Blood Adv, vol.2, pp.2904-2916, 2018.

C. L. Groomes, D. M. Gianferante, G. D. Crouch, D. S. Parekh, D. W. Scott et al., Reduction of factor VIII inhibitor titers during immune tolerance induction with recombinant factor VIII-Fc fusion protein, Pediatr Blood Cancer, vol.63, pp.922-924, 2016.

L. M. Malec, J. Journeycake, and M. V. Ragni, Extended half-life factor VIII for immune tolerance induction in haemophilia, Haemophilia, vol.22, pp.552-554, 2016.

G. Batsuli, K. L. Zimowski, K. Tickle, S. L. Meeks, and R. F. Sidonio, Immune tolerance induction in paediatric patients with haemophilia A and inhibitors receiving emicizumab prophylaxis, Haemophilia, vol.25, pp.789-796, 2019.

A. Nagao, C. Nagae, and K. Moritani, Real-world data of immune tolerance induction using recombinant factor VIII Fc fusion protein for in hemophilia A patients with inhibitors in Japan: observational Fc Adolescent and Children Treatment Study (FACTs) first interim reports, Res Pract Thromb Haemost, vol.3, pp.1-891, 2019.

A. Abraham, S. Apte, and C. Shamukhaiah, Outcome of immune tolerance induction using an extended half-life clotting factor concentrate-recombinant factor VIII Fc (Eloctate?)-a report from India, Blood, vol.132, p.2494, 2018.

M. Carcao, A. Shapiro, and N. Hwang, Real-world data of immune tolerance induction (ITI) using recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with severe hemophilia A with inhibitors at high risk for ITI failure, Haemophilia, vol.25, pp.3-77, 2019.

L. Malec, M. Carcao, and N. Jain, rFVIIIFc for first-time immune tolerance induction (ITI) therapy: interim results from the global, prospective verITI-8 study, of the International Society on Thrombosis and Haemostasis (ISTH), 2019.

A. Melbourne,

C. Königs, N. Jain, and S. Lethagen, Study design for reitirate-a prospective study of rescue ITI with recombinant factor VIII Fc (rFVIIIFc) in patients who have failed previous ITI attempts, Haemophilia, vol.24, pp.32-135, 2018.

M. Carcao, A. Shapiro, and J. M. Staber, Recombinant factor VIII Fc fusion protein for immune tolerance induction in patients with severe haemophilia A with inhibitors-a retrospective analysis, Haemophilia, vol.24, pp.245-252, 2018.

M. V. Ragni, M. Alabek, and L. M. Malec, Inhibitor development in two cousins receiving full-length factor VIII (FVIII) and FVIII-Fc fusion protein, Haemophilia, vol.22, pp.462-464, 2016.

C. Königs, R. Liesner, and M. C. Ozelo, Incidence of inhibitors in previously untreated patients with severe haemophilia A treated with rFVIIIFc: the PUPs A-LONG study, Haemophilia, vol.25, pp.25-34, 2019.

S. C. Darby, D. M. Keeling, and R. Spooner, The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, J Thromb Haemost, vol.2, pp.1047-1054, 2004.

S. C. Gouw and J. G. Van-der-bom, Marijke van den Berg H. Treatmentrelated risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study, Blood, vol.109, pp.4648-4654, 2007.

F. Peyvandi, P. M. Mannucci, and I. Garagiola, A randomized trial of factor VIII and neutralizing antibodies in hemophilia A, N Engl J Med, vol.374, pp.2054-2064, 2016.

M. V. Ragni and L. M. Malec, Design of the INHIBIT trial: preventing inhibitors by avoiding 'danger', prolonging half-life and promoting tolerance, Expert Rev Hematol, vol.7, pp.747-755, 2014.

M. V. Ragni and L. A. George, The national blueprint for future factor VIII inhibitor clinical trials: NHLBI State of the Science (SOS) Workshop on factor VIII inhibitors, Haemophilia, vol.25, pp.581-589, 2019.

K. Knobe and E. Berntorp, Haemophilia and joint disease: pathophysiology, evaluation, and management, J Comorb, vol.1, pp.51-59, 2011.

C. L. Kempton, A. Antun, and D. M. Antoniucci, Bone density in haemophilia: a single institutional cross-sectional study, Haemophilia, vol.20, pp.121-128, 2014.

G. Gerstner, M. L. Damiano, and A. Tom, Prevalence and risk factors associated with decreased bone mineral density in patients with haemophilia, Haemophilia, vol.15, pp.559-565, 2009.

H. Caviglia, M. E. Landro, G. Galatro, M. Candela, and D. Neme, Epidemiology of fractures in patients with haemophilia, Injury, vol.46, pp.1885-1890, 2015.

N. D. Gay, S. C. Lee, M. S. Liel, P. Sochacki, M. Recht et al., Increased fracture rates in people with haemophilia: a 10-year single institution retrospective analysis, Br J Haematol, vol.170, pp.584-586, 2015.

S. Bannow, B. Recht, M. Négrier, and C. , Factor VIII: long-established role in haemophilia A and emerging evidence beyond haemostasis, Blood Rev, vol.35, pp.43-50, 2019.

J. Oldenburg, R. Kulkarni, and A. Srivastava, Improved joint health in subjects with severe haemophilia A treated prophylactically with recombinant factor VIII Fc fusion protein, Haemophilia, vol.24, pp.77-84, 2018.

R. Kulkarni, A. Shapiro, and K. J. Pasi, Improved hemostasis and joint health over time in a subset of patients who did not reach optimal hemostatic control in the first year of recombinant factor VIII Fc fusion protein (rFVIIIFc) therapy, Res Pract Thromb Haemost, vol.3, pp.1-189, 2019.

J. Oldenburg, K. J. Pasi, and I. Pabinger, Improvements in joint health during long-term use of recombinant factor VIII Fc fusion protein prophylaxis in subjects with haemophilia A, Haemophilia, vol.25, pp.1-154, 2019.

J. Y. Zhou, R. Barnes, G. Foster, A. Iorio, T. J. Cramer et al., Joint bleeding tendencies in adult patients with hemophilia: it's not all pharmacokinetics, Clin Appl Thromb Hemost, vol.25, p.1076029619862052, 2019.

G. M. Rajani, Y. Lin, K. Kis-toth, R. Peters, and J. Salas, Recombinant factor VIII Fc fusion protein inhibits inflammatory osteoclast formation in vitro, Res Pract Thromb Haemost, vol.3, pp.1-228, 2019.

S. Chhabra, E. Liu, T. Kulman, and J. , How to cite this article: Meeks S, Lacroix-Desmazes S. Emerging benefits of Fc fusion technology in the context of recombinant factor VIII replacement therapy, Haemophilia, vol.135, pp.1-8, 2020.